User profiles for Kien Wei Siah
 | Kien Wei SiahMIT EECS PhD Verified email at mit.edu Cited by 1839 |
Estimation of clinical trial success rates and related parameters
… Conflict of Interest: No conflicts of interest are declared for Chi Heem Wong and Kien Wei
Siah. Andrew W. Lo has personal investments in several biotechnology companies and …
Siah. Andrew W. Lo has personal investments in several biotechnology companies and …
[BOOK][B] Machine learning with statistical imputation for predicting drug approvals
We apply machine-learning techniques to predict drug approvals using drug-development
and clinicaltrial data from 2003 to 2015 involving several thousand drug-indication pairs with …
and clinicaltrial data from 2003 to 2015 involving several thousand drug-indication pairs with …
Just how good an investment is the biopharmaceutical sector?
…, N Anaya, Y Zhang, C Vilanilam, KW Siah… - Nature …, 2017 - nature.com
Uncertainty surrounding the risk and reward of investments in biopharmaceutical companies
poses a challenge to those interested in funding such enterprises. Using data on publicly …
poses a challenge to those interested in funding such enterprises. Using data on publicly …
Machine-learning and stochastic tumor growth models for predicting outcomes in patients with advanced non–Small-Cell lung cancer
PURPOSE The prediction of clinical outcomes for patients with cancer is central to precision
medicine and the design of clinical trials. We developed and validated machine-learning …
medicine and the design of clinical trials. We developed and validated machine-learning …
Multimorbidity and mortality: A data science perspective
Background With multimorbidity becoming the norm rather than the exception, the management
of multiple chronic diseases is a major challenge facing healthcare systems worldwide. …
of multiple chronic diseases is a major challenge facing healthcare systems worldwide. …
Estimates of probabilities of successful development of pain medications: an analysis of pharmaceutical clinical development programs from 2000 to 2020
Background The authors estimate the probability of successful development and duration of
clinical trials for medications to treat neuropathic and nociceptive pain. The authors also …
clinical trials for medications to treat neuropathic and nociceptive pain. The authors also …
[PDF][PDF] Predicting drug approvals: The Novartis data science and artificial intelligence challenge
We describe a novel collaboration between academia and industry, an in-house data science
and artificial intelligence challenge held by Novartis to develop machine-learning models …
and artificial intelligence challenge held by Novartis to develop machine-learning models …
[HTML][HTML] A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates
We compare and contrast the expected duration and number of infections and deaths
averted among several designs for clinical trials of COVID-19 vaccine candidates, including …
averted among several designs for clinical trials of COVID-19 vaccine candidates, including …
Estimating probabilities of success of vaccine and other anti-infective therapeutic development programs
A key driver in biopharmaceutical investment decisions is the probability of success of a drug
development program. We estimate the probabilities of success (PoSs) of clinical trials for …
development program. We estimate the probabilities of success (PoSs) of clinical trials for …
[HTML][HTML] The reaction of sponsor stock prices to clinical trial outcomes: An event study analysis
We perform an event study analysis that quantifies the market reaction to clinical trial result
announcements for 13,807 trials from 2000 to 2020, one of the largest event studies of …
announcements for 13,807 trials from 2000 to 2020, one of the largest event studies of …